Table 3 IC50 of the 51 AJO14- derived compounds on MIA PaCa-2 cell.
From: Development of an efficient NUPR1 inhibitor with anticancer activity
Compound | IC50 (μM) | Compound | IC50 (μM) |
|---|---|---|---|
ED18 | > 100 | ED53 | > 100 |
ED21 | > 100 | ED59 | 51.2 |
ED22 | 15.2 | ED60 | 18.6 |
ED23 | 20.0 | ED61 | 9.9 |
ED24 | 29.7 | LZX-2-31 | 31.3 |
ED25 | 10.7 | LZX-2-33 | 49.3 |
ED26 | 35.0 | LZX-2-34 | 62.8 |
ED28 | 11.4 | LZX-2-35 | 11.0 |
ED29 | 19.2 | LZX-2-36 | 22.5 |
ED30 | 75.8 | LZX-2-38 | 38.6 |
ED31 | > 100 | LZX-2-39 | 23.9 |
ED32 | 24.2 | LZX-2-40 | > 100 |
ED33 | 16.1 | LZX-2-41 | 18.6 |
ED34 | 36.5 | LZX-2-44 | 64.5 |
ED35 | 70.9 | LZX-2-45 | > 100 |
ED36 | 12.5 | LZX-2-47 | 74.6 |
ED37 | 19.4 | LZX-2-52 | 14.5 |
ED38 | > 100 | LZX-2-53 | 27.5 |
ED40 | 72.0 | LZX-2-54 | 49.7 |
ED41 | > 100 | LZX-2-55 | 35.8 |
ED42 | > 100 | LZX-2-56 | 11.8 |
ED43 | > 100 | LZX-2-66 | 57.5 |
ED44 | > 100 | LZX-2-67 | 12.1 |
ED45 | > 100 | LZX-2-73 | 10.9 |
ED49 | > 100 | LZX-2-74 | > 100 |
ED50 | > 100 |
